Pharmacogenomics for covered lives
Better optimize medications for your members with RightMed®
Bring high-quality pharmacogenomic (PGx) testing to your members with RightMed for Populations. This flexible, cost-effective precision medicine solution gives you the tools to:
- Generate measurable ROI
- Improve patient outcomes
- Reduce unnecessary utilization
- Maximize your member benefits
PGx as a service with RightMed for Populations
In an increasingly complex healthcare landscape, payers, PBMs, and employers need innovative solutions to differentiate their plans and save on healthcare costs. OneOme can help.
Our end-to-end programs are tailored for your business - whether you’re a PBM that wants to add value to your employer contracts, an employer that wants to attract and retain talent with unique employee benefits, or an insurer looking for innovative ways to save on member healthcare costs.
With a focus on a variety of medical conditions such as psychiatric conditions, cancer, cardiovascular disease, pain, and more, RightMed for Populations can provide individualized insights across your member population, including for members with complex polypharmacy needs.
RightMed for Populations brings real value to your organization. We work with you to develop a program that meets the needs of your business and your members.
The RightMed difference
Fully customizable programs
Dedicated, ongoing support
How RightMed for Populations works
Your end-to-end solution for population PGx
The cornerstone of our population PGx solution is the RightMed Test, but it’s also just the beginning. We work with you to create a program tailored for your business.
Using our proprietary stratification engine and your pharmacy and medical claims data, we identify the members most likely to benefit from PGx testing. These population members often drive the highest prescription and overall healthcare spend. As such, focusing efforts on optimizing therapy for these patients can help improve outcomes and drive significant ROI through cost savings.
We offer a simple, straightforward member experience, including co-branded landing pages, configurable storefronts, regular communications, and accessible support - all surrounding our industry-leading RightMed Test.
Genetic consults for your members (with independent providers), prescriber outreach support, and clinical consults with expert clinicians all combine to help providers optimize medications for your members, based on their test results.
We track metrics including engagement, utilization, outreach, and more and provide scheduled reporting on your program. And, because populations are constantly changing, we offer restratification on a timeline of your choosing.
Why work with OneOme
We work with payers and PBMs across the U.S. to bring high-quality PGx testing and services to their members. What you can expect from our partnership:
Deep clinical experience
Our products and services are backed by expert PharmDs, MDs, laboratory professionals, and health data scientists.
The RightMed Test is grounded in significant clinical evidence, including FDA drug labels, clinical guidelines, and primary research.
We offer customized programs, flexible fee structures, and personalized support every step of the way.
Peace of mind
OneOme’s solutions are secure and HIPAA-compliant. We also follow all applicable data and genomic privacy regulations and best practices.
Get RightMed for your population
Ready to bring the power of PGx to your members? Contact us to speak with one of our experts and start building your PGx program.
The latest insights on PGx.
A quick overview of the RightMed Solution
- IQVIA Institute for Human Data Science. Medicine Use and Spending in the U.S. https://www.iqvia.com/insights/the-iqvia-institute/reports/medicine-use-and-spending-in-the-us-a-review-of-2018-and-outlook-to-2023 Published May 2019. Accessed June 10, 2020.
- Watanabe, J. H., et al. Cost of Prescription Drug–Related Morbidity and Mortality. Annals of Pharmacotherapy. 2018; 52(9), 829–837.
- Perlis et al. Pharmacogenetic Testing Among Patients With Mood and Anxiety Disorders Is Associated With Decreased Utilization and Cost: A Propensity-Score Matched Study. Depression and Anxiety. 2018; 35(10), 946–952.